search
Back to results

Breathing Exercise Against Dyspnoea in Heart Failure Patients to Improve Chemosensitivity (Breathe-HF)

Primary Purpose

Heart Failure

Status
Recruiting
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Breathing training
Sponsored by
Insel Gruppe AG, University Hospital Bern
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Heart Failure

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • New York Heart Association (NYHA) functional classes II and III
  • LVEF either ≤40% or ≥50%
  • V̇E/V̇CO2 slope ≥36, and/or a pattern of exercise oscillatory ventilation defined by established criteria
  • Optimal guideline-directed medical therapy for >3 months
  • Written informed consent

Exclusion Criteria:

  • Heart failure decompensation within the preceding 3 months
  • LVEF between 41%-49%
  • Non-cardiac conditions and comorbidities associated with hyperventilation like pulmonary diseases
  • Inability or unwillingness to perform apnoea training

Sites / Locations

  • Preventive Cardiology and Sports Medicine, Bern University Hospital, InselspitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Breathing training

Control

Arm Description

The respiratory pattern modulation training is performed at home for 12 weeks twice daily for 15 min per session and consists of three components: 1) education on abnormal ventilation in heart failure, the effect of ventilation on PaCO2 and the autonomous nervous system, and chemoreceptor sensitivity; 2) 1-3 sessions of guided and monitored face-to-face training with slow nasal abdominal breathing and intermittent apnoea supported by the Healer vest (L.I.F.E., Milan, Italy) measuring electrocardiogram (ECG), and chest excursions at the level of the xiphoid, thoracic manubrium, and abdomen; 3) independent home-based apnoea training supported by hand-outs, videos and weekly phone calls to monitor progress and adherence, answer questions and encourage further progression with duration of breath-hold.

The control group receives standard of care. They perform the study measurements before and after the intervention period of 12 weeks. They are offered to perform the breathing training after study completion.

Outcomes

Primary Outcome Measures

Ventilation to carbon dioxide production slope
Ventilation to carbon dioxide production (VE/VCO2) slope during ramp test

Secondary Outcome Measures

Nadir of ventilation to carbon dioxide production ratio
Nadir of ventilation to carbon dioxide production ratio during ramp test
Breathing frequency
Breathing frequency at rest
Pulmonary efficiency
Pulmonary deadspace ventilation to tidal ventilation (VD/VT)
Aerobic capacity
Oxygen consumption at the 1st ventilatory threshold during ramp test
Resting end-tidal carbon dioxide
Resting end-tidal carbon dioxide during resting spirometry
Chemosensitivity
Sensitivity (gain and threshold) of peripheral and central chemoreceptors to carbon dioxide during hypo- and hyperoxia
Arterialised blood bicarbonate
Bicarbonate of arterialised blood from the earlobe
Arterialised blood CO2
CO2 of arterialised blood from the earlobe
Arterialised blood O2
O2 of arterialised blood from the earlobe
Arterialised blood pH
PH of arterialised blood from the earlobe
Myocardial stress marker
NT-proBNP from venous blood as marker of myocardial stress
Heart rate variability
Heart variability at rest
Arrhythmia
Ventricular premature beats measured by 24-h electrocardiogram
Patient reported outcome
Kansas City Cardiomyopathy Questionnaire
Feasibility of breathing training
Feasibility of breathing training by patient interviews
Adherence
Adherence to breathing training by patient interviews

Full Information

First Posted
September 16, 2021
Last Updated
July 3, 2023
Sponsor
Insel Gruppe AG, University Hospital Bern
search

1. Study Identification

Unique Protocol Identification Number
NCT05057884
Brief Title
Breathing Exercise Against Dyspnoea in Heart Failure Patients to Improve Chemosensitivity
Acronym
Breathe-HF
Official Title
Breathing Exercise Against Dyspnoea in Heart Failure Patients to Improve Chemosensitivity and Ventilatory Efficiency - a Randomized Controlled Single-centre Trial
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 1, 2022 (Actual)
Primary Completion Date
March 1, 2024 (Anticipated)
Study Completion Date
September 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Insel Gruppe AG, University Hospital Bern

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
An exaggerated ventilatory response (minute ventilation, V̇E) to exercise relative to exhaled carbon dioxide (V̇CO2) is common in heart failure (HF) patients with reduced as well as preserved left ventricular ejection fraction (HFrEF, HFpEF). Severity of this exaggerated response is associated with poor prognosis. This response may be triggered by pulmonary congestion and peripheral muscle myopathy. A vicious circle is fuelled by hypersensitivity of chemoreceptors to hypercapnia and sympathetic nervous hyperactivity, resulting in hyperventilation (low PaCO2). Low PaCO2 is predictive of mortality in these patients. PaCO2 can be increased acutely, e.g. by apnoea. Also, nasal breathing has been found to reduce the V̇E/V̇CO2 slope during exercise compared to oral breathing. Three previous slow breathing studies in HFrEF patients have had encouraging results with regard to reducing sympathetic activity, reflected in lowered arterial (pulmonary) blood pressure and increased EF. The investigators hypothesise that a 12-week training with nasal slow breathing followed by end-expiratory apnoea based on education, centre-based introduction and home-based 15 min/day breathing training will be effective at reducing the exaggerated ventilatory response to exercise. A total of 68 patients with stable HF seen at the HF clinics of the Inselspital (34 HFrEF, 34 HFpEF) will be randomised to the breathing intervention or usual care. Primary outcome will be V̇E/V̇CO2 slope at 12 weeks. If breathing training successfully ameliorates the exaggerated ventilatory response and perception of dyspnea during exercise, it offers an attractive tele-health based add-on therapy that may add to or even amplify the beneficial effects of exercise training.
Detailed Description
BACKGROUND Ventilatory inefficiency, most commonly quantified as an increased ventilation (V̇E) to carbon dioxide exhalation (V̇CO2) slope during exercise, is a landmark of heart failure patients both with reduced and preserved ejection fraction (HFrEF, HFpEF).[1] Numerous studies have found higher V̇E/V̇CO2 slopes to be associated with poorer prognosis.[2-4] The components of the V̇E/V̇CO2 slope are the arterial CO2 partial pressure (PaCO2), that is affected by hyperventilation, and the pulmonary dead space/tidal volume ratio (VD/VT) that is affected by pulmonary perfusion abnormalities.[5] The exaggerated response in ventilation of HFrEF patients may be caused by hypersensitivity of chemoreceptors to CO2,[6] and/or a sympathetic nervous hyperactivity commonly found in HFrEF patients, based on an increased activation of metaboreceptors in peripheral muscles response to increased anaerobic metabolism.[7] Chronic sympathetic nervous hyperactivity has been suggested to decrease aerobic capacity of skeletal muscles based on reduced capillarisation[8] and reduced red blood cell flux[9] leading to a shift in muscle fibre type towards a lower content on type I fibres.[10] The ensuing anaerobic muscle metabolism leads to increased muscle fatiguability[11] and acidosis already at low levels of exercise, which trigger exaggerated responses in ventilation.[12] Hyperventilation, on the other hand, is well known to stimulate sympathetic nervous activity, and so the vicious circle of sympathetic nervous activity driving hyperventilation and hyperventilation activating sympathetic nervous activity continues.[13] This suggests that hyperventilation may not only be a consequence of poor left ventricular (LV) function, but also a driver. Besides pharmaceutical therapies and electrophysiological interventions, exercise therapy has been found to have beneficial effects on hemodynamic and ventilatory parameters in HFrEF[14] and HFpEF patients alike.[15] The main mechanisms of exercise are thought to be reduced peripheral resistance and hence cardiac afterload by improvement of endothelial function, increased capillarisation leading to improved oxygenation of skeletal muscles and improved aerobic metabolism.[16] Despite the beneficial effects of exercise training in both, centre-based and home-based settings,[17, 18] adherence to physical activity has been found to be poor amongst HFrEF patients.[19] Surprisingly, few studies have targeted ventilation directly with therapeutic approaches. Only three studies have assessed the effects of slow-breathing training on cardiorespiratory function.[20, 21] These studies found improved physical function, reduced blood and pulmonary arterial pressure, increased ejection fraction (EF),[20, 22] improved ventilatory efficiency[20] and reduced sleep apnoea.[22] Further, they found improved regulation of the autonomic nervous system by reducing sympathetic drive and increasing vagal activity.[23] It is unknown whether slow breathing may increase PaCO2 sufficiently to change the sensitivity or set point of chemoreceptors. On the other hand, apnoea training has been found to lead to large changes in PaCO2 levels tolerated by chemoreceptors at rest and during exercise.[24, 25] However, to date there are no published studies that have implemented apnoea into a breathing training in HF patients. Further, previous studies have not investigated whether the effect of slow breathing on improving the V̇E/V̇CO2 slope was due to a chronic increase in PaCO2 or a decrease in ventilatory dead space. HYPOTHESIS The investigators hypothesise that a 12-week training with nasal slow breathing followed by end-expiratory apnoea based on education, centre-based introduction and home-based 15 min/day breathing training will be effective at reducing the exaggerated ventilatory response to exercise. METHODS Study design Prospective randomised controlled study. Eligible patients are identified during their yearly check-up at the Heart Failure Clinic and Preventive Cardiology of the Inselspital in Bern. Patients will be randomised 1:1 (stratified for HFrEF/HFpEF and sex) to an intervention and control group. Patients in the intervention group perform the breathing training additionally to standard care and those in the control group receive standard care and are offered the breathing training after the end of the study. The study design and breathing intervention have been developed with direct input by a patient group (from pilot study). In an additional cross-sectional substudy, the same measurements of the RCT are performed in a group of 15 patients after acute or chronic coronary syndrome (ACS/CCS) with inefficient ventilation, 15 healthy age-matched and 15 healthy young controls. Further, the cross-sectional substudy compares pulmonary gas exchange and breathing patterns during 5 min of oral versus 5 min of nasal breathing during submaximal continuous exercise in the HF, ACS/CCS, old healthy, and young healthy groups. Breathing intervention The respiratory pattern modulation training is performed at home for 12 weeks twice daily for 15 min per session and consists of three components: 1) education on abnormal ventilation in heart failure, the effect of ventilation on PaCO2 and the autonomous nervous system, and chemoreceptor sensitivity; 2) 1-3 sessions of guided and monitored face-to-face training with slow nasal abdominal breathing and intermittent apnoea supported by the Healer vest (L.I.F.E., Milan, Italy) measuring electrocardiogram (ECG), and chest excursions at the level of the xiphoid, thoracic manubrium, and abdomen; 3) independent home-based apnoea training supported by hand-outs, videos and weekly phone calls to monitor progress and adherence, answer questions and encourage further progression with duration of breath-hold. Measurements Measurements are performed during visit 1 before and visit 2 at the end of the intervention period. Cardiopulmonary exercise testing (CPET) CPETs are performed on a cycle ergometer according to the recommendations of the American Heart Association.[38] Ramp tests are performed as previously described.[31] O2 consumption and CO2 production will be measured continuously in an open spirometric system (Quark, Cosmed, Rome, Italy) and registered as average values over 8 breaths. Every 2 min, patients are asked about their perception of dyspnoea on the modified Borg scale. V̇E/V̇CO2 slope from rest to ventilatory threshold 2 (VT2), peak V̇O2 and V̇O2 at VT1 are determined as previously described.[31] Blood analyses Blood samples are obtained from the antecubital vein for analysis of haemoglobin and NT-proBNP. Arterialized blood are extracted from the ear lobe at rest and peak exercise for analysis of PaCO2, oxygen (PaO2), bicarbonate and pH. Sensitivity of chemoreceptors The sensitivity of chemoreceptors is measured by a rebreathing protocol.[39] The subjects are resting supine and breathe through a mouthpiece of an open spirometric system (Innocor, Cosmed, Rome, Italy). With the 3-way-valve open to room air, the test begins with 2-5 min of hyperventilation, allowing end-tidal partial CO2 pressure (PETCO2) to drop. Following hyperventilation, the subject breathes comfortably, while the 3-way-valve is switched to the rebreathing bag. Equilibration of PCO2 in bag, lungs, and arterial blood to mixed venous blood is achieved by taking three deep breaths. During the following minutes, PETCO2 is allowed to rise, while PETO2 is clamped at 150 mmHg during hyperoxic testing, and at 50 mmHg during a second, hypoxic test run by feeding 100% O2 into the circuit by a port at the rebreathing bag. Central and peripheral chemoreflex responses to CO2 are estimated by the difference between hyperoxic and hypoxic ventilatory response.[40, 41] Patient reported outcomes The Kansas City Cardiomyopathy Questionnaire (KCCQ) are filled in during visit 1 and visit 2 to assess quality of life and dyspnoea. During visit 2, a structured interview is performed with the patient to assess feasibility and barriers with the breathing training. Adherence to training is monitored based on verbal information by the patients during the weekly phone calls. Heart rate variability (HRV) and breathing frequency (BF) HRV is measured from 24-hour ECG recorded with the Healer vest (L.I.F.E., Milan, Italy) and analysed from a segment during a deep sleep phase as previously described by the investigators' group.[42] Low-frequency power (LF, ms2, 0.04-0.15 Hz), high-frequency power (HF, ms2, 0.15-0.4 Hz), and the LF/HF are analysed [43]. BF is measured by strain gauges from Healer vest. Submaximal tests of cross-sectional substudy After a 15 min break following the CPET ramp test, patients cycle 5 min at 50% of peak power output as assessed during the ramp test with exclusively nasal, and 5 min with exclusively oral breathing in randomised order, with a 15 min break between the two tests. Pulmonary gas exchange parameters and breathing pattern are measured and compared between the two breathing modes and between the four groups (HF, ACS/CCS, old healthy, young healthy). OUTCOMES Primary outcome is V̇E/V̇CO2 slope analysed by ANCOVA with repeated measures corrected for baseline values and EF and sex. Secondary outcomes are the nadir of the V̇E/V̇CO2 ratio, breathing pattern, VD/VT, peak V̇O2, V̇O2 at VT1, resting PETCO2, peripheral and central chemoreceptor sensitivity, arterial blood gases, NT-proBNP, heart rate, HRV, ventricular premature beats from 24-hour ECG, KCCQ, feasibility and adherence. Outcomes of cross-sectional study are VE/VCO2 ratio, VE, VO2, BF, VT, PetCO2, PetO2, O2/HR and rapid shallow breathing index between nasal and oral breathing. REFERENCES Agostoni P, Guazzi M. Exercise ventilatory inefficiency in heart failure: some fresh news into the roadmap of heart failure with preserved ejection fraction phenotyping. European journal of heart failure 2017; 19(12): 1686-9. Ponikowski P, Francis DP, Piepoli MF, et al. Enhanced ventilatory response to exercise in patients with chronic heart failure and preserved exercise tolerance: marker of abnormal cardiorespiratory reflex control and predictor of poor prognosis. Circulation 2001; 103(7): 967-72. Myers J, Arena R, Oliveira RB, et al. The lowest VE/VCO2 ratio during exercise as a predictor of outcomes in patients with heart failure. Journal of cardiac failure 2009; 15(9): 756-62. Nadruz W, Jr., West E, Sengelov M, et al. Prognostic Value of Cardiopulmonary Exercise Testing in Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction. Journal of the American Heart Association 2017; 6(11). Johnson RL, Jr. Gas exchange efficiency in congestive heart failure. Circulation 2000; 101(24): 2774-6. Chua TP, Clark AL, Amadi AA, et al. Relation between chemosensitivity and the ventilatory response to exercise in chronic heart failure. Journal of the American College of Cardiology 1996; 27(3): 650-7. Scott AC, Davies LC, Coats AJ, et al. Relationship of skeletal muscle metaboreceptors in the upper and lower limbs with the respiratory control in patients with heart failure. Clinical science (London, England : 1979) 2002; 102(1): 23-30. Duscha BD, Kraus WE, Keteyian SJ, et al. Capillary density of skeletal muscle: a contributing mechanism for exercise intolerance in class II-III chronic heart failure independent of other peripheral alterations. Journal of the American College of Cardiology 1999; 33(7): 1956-63. Hirai DM, Musch TI, Poole DC. Exercise training in chronic heart failure: improving skeletal muscle O2 transport and utilization. Am J Physiol Heart Circ Physiol 2015; 309(9): H1419-39. Sullivan MJ, Duscha BD, Klitgaard H, et al. Altered expression of myosin heavy chain in human skeletal muscle in chronic heart failure. Med Sci Sports Exerc 1997; 29(7): 860-6. Schulze PC, Linke A, Schoene N, et al. Functional and morphological skeletal muscle abnormalities correlate with reduced electromyographic activity in chronic heart failure. Eur J Cardiovasc Prev Rehabil 2004; 11(2): 155-61. Piepoli M, Clark AL, Volterrani M, et al. Contribution of muscle afferents to the hemodynamic, autonomic, and ventilatory responses to exercise in patients with chronic heart failure: effects of physical training. Circulation 1996; 93(5): 940-52. Coats AJ, Clark AL, Piepoli M, et al. Symptoms and quality of life in heart failure: the muscle hypothesis. Br Heart J 1994; 72(2 Suppl): S36-9. Tucker WJ, Lijauco CC, Hearon CM, Jr., et al. Mechanisms of the Improvement in Peak VO(2) With Exercise Training in Heart Failure With Reduced or Preserved Ejection Fraction. Heart Lung Circ 2018; 27(1): 9-21. Fu TC, Yang NI, Wang CH, et al. Aerobic Interval Training Elicits Different Hemodynamic Adaptations Between Heart Failure Patients with Preserved and Reduced Ejection Fraction. Am J Phys Med Rehabil 2016; 95(1): 15-27. Hambrecht R, Niebauer J, Fiehn E, et al. Physical training in patients with stable chronic heart failure: effects on cardiorespiratory fitness and ultrastructural abnormalities of leg muscles. Journal of the American College of Cardiology 1995; 25(6): 1239-49. Ruku DM, Tran Thi TH, Chen HM. Effect of center-based or home-based resistance training on muscle strength and VO(2) peak in patients with HFrEF: A systematic review and meta-analysis. Enferm Clin (Engl Ed) 2021. Long L, Mordi IR, Bridges C, et al. Exercise-based cardiac rehabilitation for adults with heart failure. Cochrane Database Syst Rev 2019; 1(1): Cd003331. Cooper LB, Mentz RJ, Sun JL, et al. Psychosocial Factors, Exercise Adherence, and Outcomes in Heart Failure Patients: Insights From Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION). Circulation Heart failure 2015; 8(6): 1044-51. Parati G, Malfatto G, Boarin S, et al. Device-guided paced breathing in the home setting: effects on exercise capacity, pulmonary and ventricular function in patients with chronic heart failure: a pilot study. Circulation Heart failure 2008; 1(3): 178-83. Lachowska K, Bellwon J, Narkiewicz K, et al. Long-term effects of device-guided slow breathing in stable heart failure patients with reduced ejection fraction. Clinical research in cardiology : official journal of the German Cardiac Society 2019; 108(1): 48-60. Kawecka-Jaszcz K, Bilo G, Drożdż T, et al. Effects of device-guided slow breathing training on exercise capacity, cardiac function, and respiratory patterns during sleep in male and female patients with chronic heart failure. Pol Arch Intern Med 2017; 127(1): 8-15. Lachowska K, Bellwon J, Moryś J, et al. Slow breathing improves cardiovascular reactivity to mental stress and health-related quality of life in heart failure patients with reduced ejection fraction. Cardiology journal 2020; 27(6): 772-9. Roecker K, Metzger J, Scholz T, et al. Modified ventilatory response characteristics to exercise in breath-hold divers. International journal of sports physiology and performance 2014; 9(5): 757-65. 31. Marcin T, Trachsel LD, Dysli M, et al. Effect of self-tailored high-intensity interval training versus moderate-intensity continuous exercise on cardiorespiratory fitness after myocardial infarction: A randomized controlled trial. Ann Phys Rehabil Med 2021: 101490. 38. Fletcher GF, Ades PA, Kligfield P, et al. Exercise standards for testing and training: a scientific statement from the American Heart Association. Circulation 2013; 128(8): 873-934. 39. Duffin J. Measuring the respiratory chemoreflexes in humans. Respir Physiol Neurobiol 2011; 177(2): 71-9. 40. Duffin J, Mohan RM, Vasiliou P, et al. A model of the chemoreflex control of breathing in humans: model parameters measurement. Respir Physiol 2000; 120(1): 13-26. 41. Guyenet PG. Regulation of breathing and autonomic outflows by chemoreceptors. Compr Physiol 2014; 4(4): 1511-62. 42. Herzig D, Eser P, Omlin X, et al. Reproducibility of Heart Rate Variability Is Parameter and Sleep Stage Dependent. Frontiers in physiology 2017; 8: 1100. 43. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. European heart journal 1996; 17(3): 354-81.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Failure

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
68 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Breathing training
Arm Type
Experimental
Arm Description
The respiratory pattern modulation training is performed at home for 12 weeks twice daily for 15 min per session and consists of three components: 1) education on abnormal ventilation in heart failure, the effect of ventilation on PaCO2 and the autonomous nervous system, and chemoreceptor sensitivity; 2) 1-3 sessions of guided and monitored face-to-face training with slow nasal abdominal breathing and intermittent apnoea supported by the Healer vest (L.I.F.E., Milan, Italy) measuring electrocardiogram (ECG), and chest excursions at the level of the xiphoid, thoracic manubrium, and abdomen; 3) independent home-based apnoea training supported by hand-outs, videos and weekly phone calls to monitor progress and adherence, answer questions and encourage further progression with duration of breath-hold.
Arm Title
Control
Arm Type
No Intervention
Arm Description
The control group receives standard of care. They perform the study measurements before and after the intervention period of 12 weeks. They are offered to perform the breathing training after study completion.
Intervention Type
Behavioral
Intervention Name(s)
Breathing training
Intervention Description
Slow nasal breathing with intermittent end-expiratory apnoea for 15 min twice per day over 12 weeks.
Primary Outcome Measure Information:
Title
Ventilation to carbon dioxide production slope
Description
Ventilation to carbon dioxide production (VE/VCO2) slope during ramp test
Time Frame
Change from before to after 12-week breathing intervention
Secondary Outcome Measure Information:
Title
Nadir of ventilation to carbon dioxide production ratio
Description
Nadir of ventilation to carbon dioxide production ratio during ramp test
Time Frame
Change from before to after 12-week breathing intervention
Title
Breathing frequency
Description
Breathing frequency at rest
Time Frame
Change from before to after 12-week breathing intervention
Title
Pulmonary efficiency
Description
Pulmonary deadspace ventilation to tidal ventilation (VD/VT)
Time Frame
Change from before to after 12-week breathing intervention
Title
Aerobic capacity
Description
Oxygen consumption at the 1st ventilatory threshold during ramp test
Time Frame
Change from before to after 12-week breathing intervention
Title
Resting end-tidal carbon dioxide
Description
Resting end-tidal carbon dioxide during resting spirometry
Time Frame
Change from before to after 12-week breathing intervention
Title
Chemosensitivity
Description
Sensitivity (gain and threshold) of peripheral and central chemoreceptors to carbon dioxide during hypo- and hyperoxia
Time Frame
Change from before to after 12-week breathing intervention
Title
Arterialised blood bicarbonate
Description
Bicarbonate of arterialised blood from the earlobe
Time Frame
Change from before to after 12-week breathing intervention
Title
Arterialised blood CO2
Description
CO2 of arterialised blood from the earlobe
Time Frame
Change from before to after 12-week breathing intervention
Title
Arterialised blood O2
Description
O2 of arterialised blood from the earlobe
Time Frame
Change from before to after 12-week breathing intervention
Title
Arterialised blood pH
Description
PH of arterialised blood from the earlobe
Time Frame
Change from before to after 12-week breathing intervention
Title
Myocardial stress marker
Description
NT-proBNP from venous blood as marker of myocardial stress
Time Frame
Change from before to after 12-week breathing intervention
Title
Heart rate variability
Description
Heart variability at rest
Time Frame
Change from before to after 12-week breathing intervention
Title
Arrhythmia
Description
Ventricular premature beats measured by 24-h electrocardiogram
Time Frame
Change from before to after 12-week breathing intervention
Title
Patient reported outcome
Description
Kansas City Cardiomyopathy Questionnaire
Time Frame
Change from before to after 12-week breathing intervention
Title
Feasibility of breathing training
Description
Feasibility of breathing training by patient interviews
Time Frame
Change from before to after 12-week breathing intervention
Title
Adherence
Description
Adherence to breathing training by patient interviews
Time Frame
Change from before to after 12-week breathing intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: New York Heart Association (NYHA) functional classes II and III LVEF either <50% or ≥50% V̇E/V̇CO2 slope ≥36, and/or a pattern of exercise oscillatory ventilation defined by established criteria Optimal guideline-directed medical therapy for >3 months Written informed consent Exclusion Criteria: Heart failure decompensation within the preceding 3 months Non-cardiac conditions and comorbidities associated with hyperventilation like pulmonary diseases Inability or unwillingness to perform apnoea training
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Preventive Cardiology & Sports Medicine
Phone
+41 31 632 89 70
Email
kard.rehab@insel.ch
First Name & Middle Initial & Last Name or Official Title & Degree
Prisca Eser, PhD
Phone
+41 31 632 4398
Email
prisca.eser@insel.ch
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Matthias Wilhelm, Prof. MD
Organizational Affiliation
Preventive Cardiology & Sports Medicine, Dept. of Cardiology, University Hospital Berne
Official's Role
Principal Investigator
Facility Information:
Facility Name
Preventive Cardiology and Sports Medicine, Bern University Hospital, Inselspital
City
Berne
ZIP/Postal Code
3010
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Matthias Wilhelm, Prof MD
Phone
031 6328970
Email
matthias.wilhelm@insel.ch
First Name & Middle Initial & Last Name & Degree
Prisca Eser, PhD
Phone
031 632 4398
Email
prisca.eser@insel.ch
First Name & Middle Initial & Last Name & Degree
Matthias Wilhelm, Prof MD
First Name & Middle Initial & Last Name & Degree
Prisca Eser, PhD
First Name & Middle Initial & Last Name & Degree
Lukas Hunziker-Munsch, Prof MD
First Name & Middle Initial & Last Name & Degree
Christina Spengler, Prof MD PhD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Breathing Exercise Against Dyspnoea in Heart Failure Patients to Improve Chemosensitivity

We'll reach out to this number within 24 hrs